Synopsys executive chair Aart de Geus sells $21.3m in stock By Investing.com

SUNNYVALE, CA – Aart de Geus, Executive Chair of Synopsys Inc (), sold common stock totaling approximately $21.38 million in a series of transactions on August 31 and September 1, 2026. These sales followed the acquisition of shares through the exercise of stock options and an employee stock purchase plan, totaling approximately $6.75 million. The transactions come as Synopsys shares trade at $412.76, down 11.69% year-to-date, though InvestingPro analysis suggests the stock remains undervalued at current levels.

On August 31, 2026, Mr. de Geus sold 25,000 shares of Synopsys common stock at a weighted average price of $441.7646 per share. The sales occurred in multiple transactions with prices ranging from $435.88 to $445.70. On the same day, he acquired 25,000 shares through the exercise of non-qualified stock options at an exercise price of $135.88 per share. Additionally, 22 shares were acquired under the Synopsys, Inc Employee Stock Purchase Plan at a price of $360.961 per share.

The following day, September 1, 2026, Mr. de Geus sold an additional 24,641 shares of Synopsys common stock. These shares were sold at a weighted average price of $419.4401 per share, with individual transaction prices ranging from $413.99 to $430.26. Concurrently, he acquired 24,641 shares by exercising non-qualified stock options at an exercise price of $135.88 per share. The software company, valued at $79.11 billion, maintains impressive gross profit margins of 82.92% and posted 46.33% revenue growth over the last twelve months. InvestingPro offers 10 additional exclusive tips for SNPS, along with comprehensive Pro Research Reports covering this and 1,400+ other US equities.

All reported transactions were executed pursuant to a Rule 10b5-1 trading plan, which Mr. de Geus adopted on October 14, 2025.

Following these transactions, Mr. de Geus directly holds 120,443 shares of Synopsys common stock. He also indirectly holds 308,791 shares through a Family Trust and 14,500 shares through a Partnership.

In other recent news, Synopsys reported its fiscal third-quarter 2026 results, surpassing Wall Street expectations. The company achieved non-GAAP earnings of $3.91 per share on revenue of $2.48 billion, exceeding analyst predictions of $3.67 per share on revenue of $2.44 billion. Following these results, Synopsys raised its full-year outlook. Benchmark reaffirmed its Buy rating and maintained a $570 price target, noting the company’s performance as a “beat-and-raise” quarter. Additionally, Baird upgraded Synopsys to Outperform from Neutral, citing an optimistic growth outlook for fiscal 2027, with expectations of double-digit organic revenue growth. Baird also increased its price target to $560. These developments highlight the company’s strong financial performance and positive future prospects according to analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.